Publications by authors named "Keith Mikule"

Claim this Profile
D
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Matthew M Hamilton, Faika Mseeh, Timothy J McAfoos, Paul G Leonard, Naphtali J Reyna, Keith Mikule

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Barbara Czako, Joseph R Marszalek, Jason P Burke, Pijus Mandal, Paul G Leonard, Keith Mikule

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
Maria J Sambade, Amanda E D Van Swearingen, Marni B McClure, Allison M Deal, Charlene Santos, Keith Mikule

Neurooncol Adv· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Zebin Wang, Kaiming Sun, Yonghong Xiao, Bin Feng, Keith Mikule

Sci Rep· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Zebin Wang, Shaun E Grosskurth, Tony Cheung, Philip Petteruti, Jingwen Zhang, Keith Mikule

Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan

Oncotarget· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Ádám Póti, Kinga Berta, Yonghong Xiao, Orsolya Pipek, Gregory T Klus, Keith Mikule

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Jason P W Carey, Cansu Karakas, Tuyen Bui, Xian Chen, Smruthi Vijayaraghavan, Keith Mikule

Cancer Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Chungang Gu, Michelle L Lamb, Jeffrey W Johannes, Mark A Sylvester, Mark S Eisman, Keith Mikule

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Jeffrey W Johannes, Lynsie Almeida, Kevin Daly, Andrew D Ferguson, Shaun E Grosskurth, Keith Mikule

Bioorg Med Chem Lett· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Youzhi Li, Harry A Rogoff, Sarah Keates, Yuan Gao, Sylaja Murikipudi, Keith Mikule

Proc Natl Acad Sci U S A· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.
Bin Yang, Michelle L Lamb, Tao Zhang, Edward J Hennessy, Gurmit Grewal, Keith Mikule

J Med Chem· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.
Jiaquan Wu, Keith Mikule, Wenxian Wang, Nancy Su, Philip Petteruti

ACS Chem Biol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions.
Hana Blazkova, Conrad von Schubert, Keith Mikule, Rebekka Schwab, Nico Angliker

Cell Cycle· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest.
Keith Mikule, Benedicte Delaval, Philipp Kaldis, Agata Jurcyzk, Polla Hergert

Nat Cell Biol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway.
Xiangao Sun, Youzhi Li, Wei Li, Bin Zhang, A J Wang, Keith Mikule

Cell Cycle· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Centrosome control of the cell cycle.
Stephen Doxsey, Wendy Zimmerman, Keith Mikule

Trends Cell Biol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eicosanoid activation of protein kinase C epsilon: involvement in growth cone repellent signaling.
Keith Mikule, Somkiat Sunpaweravong, Jesse C Gatlin, Karl H Pfenninger

J Biol Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth cone collapse induced by semaphorin 3A requires 12/15-lipoxygenase.
Keith Mikule, Jesse C Gatlin, Becky A de la Houssaye, Karl H Pfenninger

J Neurosci· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis